Switch theme
Sign up to access all valuation multiples
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
1992
248
LTM Revenue $131M
LTM EBITDA -$213M
$343M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
bluebird bio has a last 12-month revenue of $131M and a last 12-month EBITDA of -$213M.
In the most recent fiscal year, bluebird bio achieved revenue of $83.8M and an EBITDA of -$157M.
bluebird bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See bluebird bio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $29.5M | $83.8M | XXX | XXX | XXX |
| Gross Profit | -$6.5M | -$4.0M | XXX | XXX | XXX |
| Gross Margin | -22% | -5% | XXX | XXX | XXX |
| EBITDA | -$167M | -$157M | XXX | XXX | XXX |
| EBITDA Margin | -567% | -187% | XXX | XXX | XXX |
| Net Profit | -$267M | -$212M | XXX | XXX | XXX |
| Net Margin | -904% | -253% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, bluebird bio's stock price is $5.
bluebird bio has current market cap of $46.6M, and EV of $343M.
See bluebird bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $343M | $46.6M | XXX | XXX | XXX | XXX | $-21.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, bluebird bio has market cap of $46.6M and EV of $343M.
bluebird bio's trades at 2.6x LTM EV/Revenue multiple, and -1.6x LTM EBITDA.
Analysts estimate bluebird bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for bluebird bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $343M | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | -2.2x | XXX | XXX | XXX |
| P/E | -0.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign Upbluebird bio's NTM/LTM revenue growth is 131%
bluebird bio's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, bluebird bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate bluebird bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for bluebird bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 184% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -187% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -6% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -56% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 112% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 313% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
bluebird bio acquired XXX companies to date.
Last acquisition by bluebird bio was XXXXXXXX, XXXXX XXXXX XXXXXX . bluebird bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was bluebird bio founded? | bluebird bio was founded in 1992. |
| Where is bluebird bio headquartered? | bluebird bio is headquartered in United States of America. |
| How many employees does bluebird bio have? | As of today, bluebird bio has 248 employees. |
| Who is the CEO of bluebird bio? | bluebird bio's CEO is Mr. Andrew Obenshain. |
| Is bluebird bio publicy listed? | Yes, bluebird bio is a public company listed on NAS. |
| What is the stock symbol of bluebird bio? | bluebird bio trades under BLUE ticker. |
| When did bluebird bio go public? | bluebird bio went public in 2013. |
| Who are competitors of bluebird bio? | Similar companies to bluebird bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of bluebird bio? | bluebird bio's current market cap is $46.6M |
| What is the current revenue of bluebird bio? | bluebird bio's last 12-month revenue is $131M. |
| What is the current EBITDA of bluebird bio? | bluebird bio's last 12-month EBITDA is -$213M. |
| What is the current EV/Revenue multiple of bluebird bio? | Current revenue multiple of bluebird bio is 2.6x. |
| What is the current EV/EBITDA multiple of bluebird bio? | Current EBITDA multiple of bluebird bio is -1.6x. |
| What is the current revenue growth of bluebird bio? | bluebird bio revenue growth between 2023 and 2024 was 184%. |
| Is bluebird bio profitable? | Yes, bluebird bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
